Our Managing Director, Michael Winlo shining a spotlight on obstacles within the industry, why TGA registration must be the ambition for producers and how our team at Emyria are striving to make a difference.
“Clinics and data-backed medicinal cannabis firm Emyria has embarked on a drug-development program of its own. Here, chief executive Dr Michael Winlo tells Cannabiz that TGA registration must be the ambition for producers, and suggests why some may be unwilling to invest in research.”